MP
LVACW

Mangrove Partners’s LAVA Medtech Acquisition Corp. Warrants LVACW Stock Holding History

Mangrove Partners’s Portfolio LVACW Stock Details LVACW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-200,000
Closed -$1.99M – 538
2022
Q2 		$1.99M Buy
+200,000
New +$40.8K 0.1% 308

Other funds holding LVACW

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
EFI
EHP Funds Inc Toronto, Canada $43.6M AUM 69.08% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
FBCM
Fort Baker Capital Management Larkspur, California $1.27B AUM 25.46% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
PMAM
Picton Mahoney Asset Management Toronto, Ontario, Canada $13.5B AUM 50.48% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return

Mangrove Partners's LVACW Position: Q3 2022 in Review

Mangrove Partners sold out of LAVA Medtech Acquisition Corp. Warrants (LVACW) in Q3 2022, closing a stake of 200,000 shares — an estimated $1.99M sold.

Mangrove Partners first reported a position in LVACW in Q2 2022 and held it in 1 quarter. The position peaked at $1.99M in Q2 2022. 31 funds tracked by Wall St. Rank hold LVACW as of Q3 2022.

  • Mangrove Partners reported no remaining LAVA Medtech Acquisition Corp. Warrants position as of Q3 2022 after selling out during the quarter.
  • Mangrove Partners sold 200,000 LAVA Medtech Acquisition Corp. Warrants shares in Q3 2022, an estimated $1.99M.
  • Mangrove Partners first reported a position in LAVA Medtech Acquisition Corp. Warrants in Q2 2022 and held it in 1 quarter.
  • Mangrove Partners's LAVA Medtech Acquisition Corp. Warrants position peaked at $1.99M in Q2 2022.
  • 31 funds tracked by Wall St. Rank held LAVA Medtech Acquisition Corp. Warrants as of Q3 2022.

Based on Mangrove Partners's 13F filing for Q3 2022, filed 14 Nov 2022.